Natural Product (NP) Details
General Information of the NP (ID: NP0060) | |||||
---|---|---|---|---|---|
Name |
Norcantharidin
|
||||
Synonyms |
Norcantharidin; 5442-12-6; 29745-04-8; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; Endothall anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-; NCTD; 3,6-Endoxohexahydrophthalic anhydride; (+/-)-NCTD; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; Norcantharadine; (+/-)-Norcantharidin; Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; 4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione; 4,10-dioxatricyclo[5.2.1.0<2,6>]decane-3,5-dione; exo-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; DEMETHYL-CANTHARIDIN; Isocantharidin; MFCD00213361; 3, hexahydro-; NSC 14003; Norcantharidin, solid; Spectrum_001667; 3,6-Endooxyphthalic anhydride, hexahydro-; SpecPlus_000904; Phthalic anhydride, hexahydro-3,6-endoxo-; 4,3-dione, hexahydro-; Spectrum2_001683; Spectrum3_001634; Spectrum4_000601; Spectrum5_001514; CHEMBL8327; Lopac0_000830; BSPBio_003327; KBioGR_001122; KBioSS_002147; Phthalic anhydride,6-endoxo-; MLS002153470; DivK1c_007000; SCHEMBL177729; SPECTRUM1504153; SPBio_001606; KBio1_001944; KBio2_002147; KBio2_004715; KBio2_007283; KBio3_002547; DTXSID30884158; HMS3262F21; HMS3370H07; 4,7-Epoxyisobenzofuran-1,3-dione; BCP09826; BCP25426; HY-N0585; NSC14003; NSC59023; Tox21_500830; WLN: T C555 A AO DVOVTJ; CCG-39454; NSC-14003; NSC-59023; NSC148536; s3759; SBB005955; STK424286; Hexahydro-3,6-epoxyphthalic anhydride; AKOS003267901; FS-4623; LP00830; MCULE-7561066553; NSC-148536; SDCCGSBI-0050807.P003; NCGC00015756-03; NCGC00015756-04; NCGC00015756-05; NCGC00015756-06; NCGC00015756-07; NCGC00015756-08; NCGC00015756-09; NCGC00015756-14; NCGC00094161-01; NCGC00094161-02; NCGC00094161-03; NCGC00094161-04; NCGC00094161-05; NCGC00094161-06; NCGC00261515-01; NCI60_001019; SMR000326693; ST057264; DB-050518; CS-0009119; EU-0100830; FT-0614776; FT-0621477; FT-0626378; N1662; hexahydro-4,7-epoxy-2-benzofuran-1,3-dione; N 8784; 3,6-Endoxohexahydrophthalic anhydride, exo isomer; SR-01000076037; SR-01000076037-1; 4,10-dioxatricyclo[5.2.1.0?,?]decane-3,5-dione; BRD-A66914119-001-04-0; Q15425762; 4,10-Dioxa-tricyclo[5.2.1.02,6]decane-3,5-dione; 3-(5'-(4-(diphenylamino)phenyl)-[2,2'-bithiophen]-5-yl)cyclohex-2-enone; EXO-7-OXA-BICYCLO(2.2.1)-HEPTANE-2,3-DICARBOXYLIC ANHYDRIDE; Exo-cis-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; Endothall anhydride; 51154-98-4; TIMTEC-BB SBB005955;4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-;4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione
Click to Show/Hide
|
||||
Species Origin | Epicauta pensylvanica ... | Click to Show/Hide | |||
Epicauta pensylvanica | |||||
Disease | Renal fibrosis [ICD-11: MF54] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C8H8O4
|
||||
PubChem CID | |||||
Canonical SMILES |
C1CC2C3C(C1O2)C(=O)OC3=O
|
||||
InChI |
1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2
|
||||
InChIKey |
JAABVEXCGCXWRR-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 5442-12-6
|
||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Crizotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | MET | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MHCC97-H | CVCL_4972 | Adult hepatocellular carcinoma | Homo sapiens | ||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | For a xenograft model, 2*106 human HepG2 cells were injected subcutaneously into the right flanks of the mice into the right flanks of the mice. | |||||
Experimental
Result(s) |
Cytotoxic autophagy resulting from inhibition of c-Met/mTOR signaling may be achieved in HCC by combined NCTD and crizotinib administration. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Phosphatase 2A PR61alpha (PPP2R5A) | Molecule Info | [3] | |
Serine/threonine PP1-alpha (PPP1CA) | Molecule Info | [4] | ||
KEGG Pathway | mRNA surveillance pathway | Click to Show/Hide | ||
2 | Sphingolipid signaling pathway | |||
3 | Oocyte meiosis | |||
4 | PI3K-Akt signaling pathway | |||
5 | AMPK signaling pathway | |||
6 | Adrenergic signaling in cardiomyocytes | |||
7 | Dopaminergic synapse | |||
Panther Pathway | EGF receptor signaling pathway | Click to Show/Hide | ||
2 | FGF signaling pathway | |||
3 | Wnt signaling pathway | |||
Pathway Interaction Database | Canonical Wnt signaling pathway | Click to Show/Hide | ||
2 | C-MYC pathway | |||
3 | Validated transcriptional targets of deltaNp63 isoforms | |||
Reactome | Degradation of beta-catenin by the destruction complex | Click to Show/Hide | ||
2 | Separation of Sister Chromatids | |||
3 | Resolution of Sister Chromatid Cohesion | |||
4 | CTLA4 inhibitory signaling | |||
5 | Platelet sensitization by LDL | |||
6 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
7 | S33 mutants of beta-catenin aren't phosphorylated | |||
8 | S37 mutants of beta-catenin aren't phosphorylated | |||
9 | S45 mutants of beta-catenin aren't phosphorylated | |||
10 | T41 mutants of beta-catenin aren't phosphorylated | |||
11 | RHO GTPases Activate Formins | |||
12 | RAF activation | |||
13 | Negative regulation of MAPK pathway | |||
14 | Mitotic Prometaphase | |||
WikiPathways | Glycogen Metabolism | Click to Show/Hide |

